Votoplam not checked
Novartis · HTT227 · HTT227 / PTC518
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Votoplam will be administered per dose and schedule specified in the arm.”In the company’s words, NCT06254482 on ClinicalTrials.gov
- Tested for
- Huntington Disease (2 trials)
- Main trialPhase 3
- “The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.”In the company’s words, NCT07326709 on ClinicalTrials.gov
- Other names
- HTT227 · HTT227 / PTC518 · PTC518
Other drugs for Huntington Disease
- SKY-0515Skyhawk Therapeutics, Inc. · Phase 2/3
- ValbenazineNeurocrine Biosciences · Phase 3
- PridopidinePrilenia · Phase 3
- VO659Vico Therapeutics B. V. · Phase 1/2
- ER2001ExoRNA Bioscience · Phase 1/2
- TominersenRoche · Phase 2
Coming up2
- 16 Jul 2029Phase 2 trial completes · ClinicalTrials.gov
- 2 Apr 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 2 Apr 2030 | A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease | |
| Phase 2Active, not recruiting | 16 Jul 2029 | An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) | |
| Phase 2Completed | 7 Feb 2025 | A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026